News from regulus therapeutics inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 26, 2014, 16:05 ET

Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference

 Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Nov 15, 2014, 18:00 ET
Nov 06, 2014, 16:05 ET

Regulus to Present at the Credit Suisse Healthcare Conference

 Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Nov 05, 2014, 16:05 ET

Regulus Reports Third Quarter 2014 Financial Results and Recent Highlights

 Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Nov 03, 2014, 16:05 ET

Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

 Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Oct 30, 2014, 16:05 ET

Regulus Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call

 Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Oct 28, 2014, 20:10 ET

Regulus Announces Pricing of Public Offering of Common Stock

 Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today...

Oct 27, 2014, 16:00 ET

Regulus Announces Commencement of Public Offering of Common Stock

 Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today...

Oct 22, 2014, 07:30 ET
Oct 14, 2014, 08:00 ET

Regulus Presents New Preclinical Data on Multiple Programs and Provides Portfolio Overview at 10th Annual Oligonucleotide Therapeutics Society (OTS) Meeting

 Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Sep 24, 2014, 08:00 ET

Regulus Announces Notice of Allowance from U.S. Patent Office Related to microRNA-103/107 Program in Metabolic Disorders

 Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Sep 18, 2014, 08:00 ET

Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients

 Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Aug 07, 2014, 16:05 ET

Regulus to Present at the Wedbush Life Sciences Management Access Conference

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Aug 06, 2014, 16:05 ET

Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights

 Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Aug 05, 2014, 08:00 ET

Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis

 Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs,...

Jul 30, 2014, 16:05 ET

Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Jul 21, 2014, 08:00 ET

Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome

 Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Jun 25, 2014, 08:00 ET

Regulus Announces Patent Grant from U.S. Patent Office in Sarnow Patent Estate on microRNA Therapeutics for the Treatment of HCV

 Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

Jun 16, 2014, 08:00 ET
Regulus Therapeutics Inc. Appoints Paul C. Grint, M.D. as Chief Medical Officer (PRNewsFoto/Regulus Therapeutics Inc.)

Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...

May 09, 2014, 16:05 ET

Regulus to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...